Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 53Lymphoma, Mantle-Cell 34Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Follicular 18Lymphoma 15Lymphoma, Non-Hodgkin 13Waldenstrom Macroglobulinemia 12Lymphoma, B-Cell 12Recurrence 9Lymphoma, B-Cell, Marginal Zone 9Leukemia 6Bronchiolitis Obliterans Syndrome 6Multiple Myeloma 5Leukemia, Lymphoid 5Leukemia, B-Cell 5Hodgkin Disease 5Hematologic Neoplasms 4Burkitt Lymphoma 4Neoplasms 3Graft vs Host Disease 3Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Chromosome 17 deletion 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1

Interventions

Cyclophosphamide 62Dexamethasone 60Melphalan 54Peripheral Blood Stem Cell Transplantation 49Bortezomib 40Busulfan 39fludarabine phosphate 34Filgrastim 32Lenalidomide 30Thalidomide 27Tacrolimus 25Antilymphocyte Serum 23Radiotherapy 22Mycophenolic Acid 17Methotrexate 17Prednisone 15Etoposide 15sargramostim 14Cyclosporine 14fludarabine 12Methylprednisolone 11Granulocyte Colony-Stimulating Factor 11Calcium Dobesilate 11Whole-Body Irradiation 10Doxorubicin 9Carmustine 9pomalidomide 8Vincristine 8Interferon-alpha 8Cord Blood Stem Cell Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms, Plasma Cell × ibrutinib × Clear all
NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Alliance Foundation Trials, LLC.

Phase 1 Completed
14 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡